RxDoctor Payments Data

James Shackson, MD

Psychiatry · Blue Ash, OHNPI 1831185545

Payments from drug & device makers

$1,246in general payments, 2019–2025

Across 26 payments — averaging $47.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuronetics, Inc.$395
  • Acadia Pharmaceuticals Inc$321
  • Neurocrine Biosciences, Inc.$293
  • Teva Pharmaceuticals USA, Inc.$132
  • Biogen$24
  • Lilly USA, LLC$23
  • plus $57 from 3 others

What the payments were for

  • Food & beverage$85168%
  • Other$39532%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,246 in reported general payments places this provider in the 70th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$65,903
Medicare patients
505
Services billed
908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate42$172,060
NuedextaDextromethorphan Hbr/Quinidine29$32,230
Memantine Hcl306$9,904
Galantamine Hbr120$6,712
Sertraline Hcl571$5,937
TrintellixVortioxetine Hydrobromide12$5,222
Olanzapine222$5,125
Paliperidone ErPaliperidone14$3,799
Galantamine ErGalantamine Hbr29$3,619
Risperidone259$3,407
Duloxetine Hcl101$2,655
Divalproex Sodium82$2,511
Aripiprazole85$2,195
Ziprasidone Hcl20$2,096
Donepezil Hcl117$1,990

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$293$172,06042 claims
Avanir Pharmaceuticals, Inc.Nuedexta$20$32,23029 claims
Lilly USA, LLCOlanzapine$23$5,125222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Blue Ash

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →